Release the Power of Exosomes

Extracellular Vesicles (EVs), also known as exosomes, are nanometer-sized particles naturally secreted by various cells. Exosomes have the potential to act as therapeutic messengers between cells.
Therapeutic exosomes are released by cultured cells. They are considered a safer, more consistent, and more stable alternative to current cell-based therapeutic approaches. In addition, they could be highly cost-effective.

Triple Axis Strategy

1. Focus on Rare Diseases to Address High Unmet Medical Needs

Developing therapies for rare inflammatory diseases currently not responding to the Standard of Care.

Learn More Learn More
2. Innovative Drug Loading and Delivery Platform

Maximizing the therapeutic potential of exosomes by enabling them to be loaded with specific therapeutic molecules and drugs.

Learn More Learn More
3. State-of-the-Art GMP Platform

Providing high-quality EVs and exosomes from research to clinical use through our advanced GMP Manufacturing platform.

Learn More Learn More

Rare Inflammatory Diseases

Using our potential drug candidate, EVs, and exosomes derived from cultured human umbilical cord mesenchymal stromal cells (MSCs), we intend to demonstrate the benefit of therapeutic Evs and exosomes for rare inflammatory diseases.

Today, 90% of Rare Diseases have no adequate treatment, affecting over 350 million people worldwide.

Our lead indication is bronchopulmonary dysplasia in preterm babies.

Learn more

Harnessing the Power of Exosomes

Exosomes offer a unique capability to deliver therapeutic molecules and drugs to specific cells and organs, including the brain, immune system, and lungs.

We are developing our production platform to load exosomes with therapeutic molecules, such as RNAs, proteins, and chemical drug compounds, for safer and more effective targeted therapies.

Learn more

Automated Large-scale Production Platform

We have developed a state-of-the-art GMP manufacturing site dedicated to exosomes, validated for R&D and clinical use, enabling us to supply high-quality exosomes to other research organizations.

Our fully automated large-scale platform is being upgraded to load therapeutic molecules, enabling other research organizations and us to develop innovative therapies.

Learn more